- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer in Argentina
Total 15 results
-
Hoffmann-La RocheRecruitingEstrogen Receptor-Positive, HER2-Negative Advanced Breast CancerBelgium, Korea, Republic of, United States, Canada, China, Italy, France, Brazil, Australia, Argentina, Hong Kong, Portugal, Spain, Taiwan, India, Costa Rica, Israel, Thailand, Germany, New Zealand, Poland, Chile, Colombia, Guatemala, H...
-
Hoffmann-La RocheActive, not recruitingEstrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast CancerUnited States, Korea, Republic of, China, Poland, Taiwan, Turkey, United Kingdom, Australia, Argentina, Germany, Singapore, Thailand, Israel, Russian Federation, Ukraine, Brazil, South Africa
-
Hoffmann-La RocheActive, not recruitingEstrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast CancerUnited States, Italy, Korea, Republic of, Canada, Germany, United Kingdom, Australia, Belgium, Brazil, China, Denmark, France, Hong Kong, Portugal, Spain, Taiwan, Turkey, Japan, Argentina, Mexico, Israel, Poland, Russian Federation, A... and more
-
Genentech, Inc.RecruitingEstrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast CancerKorea, Republic of, United States, Spain, Taiwan, United Kingdom, Japan, Germany, Argentina, Turkey, Greece, Italy, Singapore, South Africa
-
Olema Pharmaceuticals, Inc.RecruitingBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | HER2 Negative Breast Carcinoma | ER Positive Breast CancerUnited States, Korea, Republic of, Australia, Taiwan, Hong Kong, Malaysia, Thailand, Argentina, Belgium, Portugal, Italy, Czechia, Mexico, Poland
-
Eli Lilly and CompanyCompletedHER-2 Positive Breast Cancer | Hormone Receptor Positive Breast CancerSpain, United States, Korea, Republic of, Belgium, France, Germany, Italy, Australia, Argentina, Canada, United Kingdom, Mexico, Brazil, Greece
-
Synta Pharmaceuticals Corp.CompletedBreast Cancer | Triple Negative Breast Cancer | HER-2 Positive Breast Cancer | ER/Progressive Response (PR) + Refractory to Prior Hormonal TreatmentSpain, United States, Argentina, Belgium, Brazil, Korea, Republic of, Peru, United Kingdom
-
Novartis PharmaceuticalsCompletedHormone Receptor Positive Breast CancerUnited States, Argentina, Thailand, Japan, France, Korea, Republic of, Spain, Turkey, Hungary, United Kingdom, Portugal, Brazil, Netherlands
-
AstraZenecaActive, not recruitingHormone Receptor Positive Breast CancerCanada, Spain, United States, Romania, Taiwan, Italy, Brazil, Peru, Russian Federation, China, Czechia, Ukraine, South Africa, Japan, Poland, Mexico, United Kingdom, Argentina, Slovakia, Turkey
-
Hoffmann-La RocheCompletedHER2-Positive Early Breast CancerUnited States, Finland, Hong Kong, Panama, Portugal, Spain, Mexico, Sweden, Brazil, Serbia, Argentina, Lebanon, Cuba, Qatar, Saudi Arabia, Chile, Jordan
-
AstraZenecaDaiichi SankyoActive, not recruitingBreast Cancer; HER2-positive; MetastaticUnited States, Belgium, Canada, Denmark, Italy, Spain, Hungary, Taiwan, Turkey, France, Germany, Korea, Republic of, Brazil, India, Japan, Peru, Philippines, United Kingdom, China, South Africa, Israel, Russian Federation, Argentina, ... and more
-
Gilead SciencesMerck Sharp & Dohme LLCRecruitingTriple Negative Breast Cancer | PD-L1 PositiveUnited States, Taiwan, Belgium, Australia, Austria, Israel, Spain, Italy, Korea, Republic of, Japan, France, Netherlands, Canada, Turkey, Germany, Malaysia, Singapore, United Kingdom, Hong Kong, Hungary, Mexico, Switzerland, Puerto... and more
-
Novartis PharmaceuticalsCompletedMetastatic Breast Cancer | HER2/Neu Over-expressing Locally Advanced Breast CancerChina, United States, France, Hungary, Turkey, Japan, Germany, Singapore, Italy, Poland, Spain, United Kingdom, Thailand, Israel, Australia, Belgium, Greece, Argentina, Czech Republic, Mexico, Slovakia
-
Daiichi Sankyo, Inc.AstraZeneca; NSABP Foundation Inc; German Breast Group; Spanish Breast Cancer Research...Active, not recruitingHER2-Positive Primary Breast Cancer | Residual Invasive Breast CancerUnited States, Spain, France, Germany, Korea, Republic of, United Kingdom, Denmark, Israel, Belgium, Taiwan, Chile, Italy, Japan, Peru, Portugal, China, Turkey, Canada, Ireland, Australia, Greece, Czechia, Singapore, Poland, Romania, Arge... and more
-
Merck Sharp & Dohme LLCEisai Inc.Active, not recruitingGlioblastoma | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Advanced Solid Tumors | Triple Negative Breast Cancer | Biliary Tract CancersUnited States, Argentina, Australia, Canada, Chile, Colombia, France, Germany, Israel, Italy, Korea, Republic of, Russian Federation, Spain, Switzerland, Taiwan, Thailand, United Kingdom